NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have received a consensus rating of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $8.50.

NRSN has been the topic of a number of recent research reports. D. Boral Capital reissued a “buy” rating and set a $14.00 price target on shares of NeuroSense Therapeutics in a research note on Wednesday, April 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research note on Friday, May 8th.

NeuroSense Therapeutics Stock Down 2.6%

Shares of NRSN stock opened at $0.68 on Monday. NeuroSense Therapeutics has a twelve month low of $0.63 and a twelve month high of $2.10. The stock’s fifty day simple moving average is $0.77 and its 200 day simple moving average is $0.82. The firm has a market capitalization of $22.27 million, a P/E ratio of -1.27 and a beta of 1.58.

Insider Buying and Selling

In other NeuroSense Therapeutics news, CEO Alon Ben-Noon purchased 250,000 shares of the company’s stock in a transaction dated Tuesday, June 16th. The stock was purchased at an average price of $0.80 per share, with a total value of $200,000.00. Following the completion of the purchase, the chief executive officer owned 4,534,233 shares of the company’s stock, valued at approximately $3,627,386.40. The trade was a 5.84% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Or Eisenberg purchased 250,000 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were acquired at an average cost of $0.80 per share, with a total value of $200,000.00. Following the purchase, the chief financial officer directly owned 1,504,050 shares of the company’s stock, valued at approximately $1,203,240. The trade was a 19.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 27.40% of the company’s stock.

Institutional Trading of NeuroSense Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of NRSN. Squarepoint Ops LLC lifted its holdings in NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after buying an additional 45,450 shares during the period. Jane Street Group LLC acquired a new stake in shares of NeuroSense Therapeutics in the second quarter valued at about $54,000. Two Sigma Investments LP bought a new position in shares of NeuroSense Therapeutics during the third quarter worth about $26,000. Finally, Yorkville Advisors Global LP bought a new position in shares of NeuroSense Therapeutics during the fourth quarter worth about $77,000. 1.04% of the stock is currently owned by institutional investors and hedge funds.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.